DK175215B1 - Fast farmaceutisk præparat med langvarig afgivelse af det aktive stof samt fremgangsmåde til fremstilling deraf - Google Patents
Fast farmaceutisk præparat med langvarig afgivelse af det aktive stof samt fremgangsmåde til fremstilling deraf Download PDFInfo
- Publication number
- DK175215B1 DK175215B1 DK198700148A DK14887A DK175215B1 DK 175215 B1 DK175215 B1 DK 175215B1 DK 198700148 A DK198700148 A DK 198700148A DK 14887 A DK14887 A DK 14887A DK 175215 B1 DK175215 B1 DK 175215B1
- Authority
- DK
- Denmark
- Prior art keywords
- long
- weight
- xanthan gum
- term release
- composition according
- Prior art date
Links
- 239000007787 solid Substances 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title claims description 38
- 239000013543 active substance Substances 0.000 title claims description 13
- 238000000034 method Methods 0.000 title claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 6
- 230000002035 prolonged effect Effects 0.000 title description 6
- 239000000203 mixture Substances 0.000 claims abstract description 94
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 57
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 50
- 239000000230 xanthan gum Substances 0.000 claims abstract description 50
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 50
- 239000002831 pharmacologic agent Substances 0.000 claims abstract description 28
- 230000007774 longterm Effects 0.000 claims description 89
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 31
- 229960001680 ibuprofen Drugs 0.000 claims description 29
- 229960002390 flurbiprofen Drugs 0.000 claims description 17
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 9
- 229920000057 Mannan Polymers 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 claims description 5
- 210000002784 stomach Anatomy 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 4
- 239000008247 solid mixture Substances 0.000 claims description 4
- 241001474374 Blennius Species 0.000 claims description 3
- 210000000936 intestine Anatomy 0.000 claims description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims description 3
- 235000012239 silicon dioxide Nutrition 0.000 claims description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 2
- 238000002156 mixing Methods 0.000 abstract description 5
- 238000013268 sustained release Methods 0.000 abstract description 3
- 239000012730 sustained-release form Substances 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 description 62
- 239000003814 drug Substances 0.000 description 29
- 229940079593 drug Drugs 0.000 description 27
- 239000000546 pharmaceutical excipient Substances 0.000 description 19
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 17
- 239000000499 gel Substances 0.000 description 17
- 239000004480 active ingredient Substances 0.000 description 16
- 239000002552 dosage form Substances 0.000 description 13
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 12
- 239000000470 constituent Substances 0.000 description 10
- 229920001971 elastomer Polymers 0.000 description 10
- 239000005060 rubber Substances 0.000 description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- 239000008101 lactose Substances 0.000 description 9
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 9
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 9
- 235000021355 Stearic acid Nutrition 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 8
- 239000008117 stearic acid Substances 0.000 description 8
- 239000012736 aqueous medium Substances 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 6
- 229920003072 Plasdone™ povidone Polymers 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 239000007909 solid dosage form Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 5
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 229960000905 indomethacin Drugs 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 235000010413 sodium alginate Nutrition 0.000 description 5
- 239000000661 sodium alginate Substances 0.000 description 5
- 229940005550 sodium alginate Drugs 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 229960000278 theophylline Drugs 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000008119 colloidal silica Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000003628 erosive effect Effects 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 230000000887 hydrating effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229960004503 metoclopramide Drugs 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 241000589636 Xanthomonas campestris Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 229940069428 antacid Drugs 0.000 description 2
- 239000003159 antacid agent Substances 0.000 description 2
- 230000001458 anti-acid effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000007580 dry-mixing Methods 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- -1 hydroxypropyl Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 101150029062 15 gene Proteins 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- BALXUFOVQVENIU-GNAZCLTHSA-N Ephedrine hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-GNAZCLTHSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229920002678 cellulose Chemical class 0.000 description 1
- 239000001913 cellulose Chemical class 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000010514 hydrogenated cottonseed oil Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000865 membrane-inlet mass spectrometry Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- IRQVJPHZDYMXNW-UHFFFAOYSA-N metoclopramide dihydrochloride monohydrate Chemical compound O.[Cl-].[Cl-].CC[NH+](CC)CCNC(=O)C1=CC(Cl)=C([NH3+])C=C1OC IRQVJPHZDYMXNW-UHFFFAOYSA-N 0.000 description 1
- 229960000923 metoclopramide hydrochloride Drugs 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000001072 progestational effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000003236 psychic effect Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000012958 reprocessing Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000007892 solid unit dosage form Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical class C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8601204 | 1986-01-18 | ||
| GB868601204A GB8601204D0 (en) | 1986-01-18 | 1986-01-18 | Therapeutic agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK14887D0 DK14887D0 (da) | 1987-01-13 |
| DK14887A DK14887A (da) | 1987-07-19 |
| DK175215B1 true DK175215B1 (da) | 2004-07-12 |
Family
ID=10591589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK198700148A DK175215B1 (da) | 1986-01-18 | 1987-01-13 | Fast farmaceutisk præparat med langvarig afgivelse af det aktive stof samt fremgangsmåde til fremstilling deraf |
Country Status (23)
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1191674B (it) * | 1986-03-07 | 1988-03-23 | Eurand Spa | Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale |
| US4792452A (en) * | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| US4994276A (en) * | 1988-09-19 | 1991-02-19 | Edward Mendell Co., Inc. | Directly compressible sustained release excipient |
| US5169639A (en) * | 1988-09-19 | 1992-12-08 | Edward Mendell Co., Inc. | Controlled release verapamil tablets |
| US5128143A (en) * | 1988-09-19 | 1992-07-07 | Edward Mendell Co., Inc. | Sustained release excipient and tablet formulation |
| US5009895A (en) * | 1990-02-02 | 1991-04-23 | Merck & Co., Inc. | Sustained release with high and low viscosity HPMC |
| IT1250483B (it) * | 1990-08-30 | 1995-04-07 | Eurand Int | Sistema di ritardo a matrice multipla |
| DE4140184C2 (de) * | 1991-12-05 | 1995-12-21 | Alfatec Pharma Gmbh | Akutform für ein Flurbiprofen enthaltendes Arzneimittel |
| DE4140183C2 (de) * | 1991-12-05 | 1995-12-21 | Alfatec Pharma Gmbh | Retardform für ein Flurbiprofen enthaltendes Arzneimittel |
| DE4140172C2 (de) * | 1991-12-05 | 1995-12-21 | Alfatec Pharma Gmbh | Retardform für ein Ibuprofen enthaltendes Arzneimittel |
| DE4140179C2 (de) * | 1991-12-05 | 1995-12-21 | Alfatec Pharma Gmbh | Akutform für ein Ibuprofen enthaltendes Arzneimittel |
| DE4140192C2 (de) * | 1991-12-05 | 1996-02-29 | Alfatec Pharma Gmbh | Sol-gesteuerte Thermokolloidmatrix auf Gelatinebasis für perorale Retardformen |
| US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
| US5292534A (en) * | 1992-03-25 | 1994-03-08 | Valentine Enterprises, Inc. | Sustained release composition and method utilizing xanthan gum and an active ingredient |
| US5472711A (en) * | 1992-07-30 | 1995-12-05 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
| AU5745394A (en) * | 1992-12-30 | 1994-08-15 | Fmc Corporation | Readily available konjac glucomannan sustained release excipient |
| US5773025A (en) | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
| US5455046A (en) * | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
| US5662933A (en) | 1993-09-09 | 1997-09-02 | Edward Mendell Co., Inc. | Controlled release formulation (albuterol) |
| US6726930B1 (en) * | 1993-09-09 | 2004-04-27 | Penwest Pharmaceuticals Co. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
| US5464067A (en) * | 1994-01-11 | 1995-11-07 | Dulak; Joseph O. | Golf marker cleaner and grass remover |
| US6395303B1 (en) * | 1996-06-10 | 2002-05-28 | Edward Mendell Co., Inc. | Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose |
| FR2729857B1 (fr) * | 1995-01-27 | 1997-04-04 | Rhone Poulenc Chimie | Compositions pharmaceutiques sous forme de comprimes a liberation prolongee a base de granules en polysaccharides de haut poids moleculaire |
| WO1997026865A1 (en) * | 1996-01-29 | 1997-07-31 | Edward Mendell Co., Inc. | Sustained release excipient |
| US5637625A (en) * | 1996-03-19 | 1997-06-10 | Research Triangle Pharmaceuticals Ltd. | Propofol microdroplet formulations |
| KR100321489B1 (ko) | 1996-07-08 | 2002-10-09 | 에드워드 멘델 컴파니 인코포레이티드 | 고용량의불용성약물용서방성매트릭스 |
| IN186245B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1997-09-19 | 2001-07-14 | Ranbaxy Lab Ltd | |
| US6607751B1 (en) * | 1997-10-10 | 2003-08-19 | Intellipharamaceutics Corp. | Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum |
| US6056977A (en) | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
| US20030153623A1 (en) * | 1998-07-22 | 2003-08-14 | Yamanouchi Pharmaceutical Co., Ltd. | Solid preparation containing sparingly soluble NSAIDs |
| GB9816723D0 (en) * | 1998-08-01 | 1998-09-30 | Boots Co Plc | Therapeutic agents |
| ATE424810T1 (de) | 1998-12-11 | 2009-03-15 | Nostrum Pharmaceuticals Inc | Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung |
| US7250176B1 (en) | 1999-04-13 | 2007-07-31 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection |
| US6294199B1 (en) | 1999-04-13 | 2001-09-25 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising administering amoxycillin |
| KR100463496B1 (ko) | 1999-09-30 | 2005-01-06 | 펜웨스트 파머슈티칼즈 컴파니 | 고가용성 약물용 서방성 메트리스 시스템 |
| US7235258B1 (en) * | 1999-10-19 | 2007-06-26 | Nps Pharmaceuticals, Inc. | Sustained-release formulations for treating CNS-mediated disorders |
| EP1284729A4 (en) * | 2000-04-13 | 2007-12-19 | Mayo Foundation | REDUCTION AGENTS OF A (BETA) 42 |
| AU8456101A (en) * | 2000-08-22 | 2002-03-04 | Agres Ltd | A release composition and method of preparation |
| US20040102328A1 (en) * | 2000-08-22 | 2004-05-27 | Johnson Von Walter | Thermo-stable bio-matrix |
| WO2002030392A2 (en) | 2000-10-12 | 2002-04-18 | Beecham Pharmaceuticals (Pte) Limited | Formulation containing amoxicillin |
| US6756057B2 (en) | 2000-10-12 | 2004-06-29 | Beecham Pharmaceuticals (Pte) Limited | Amoxicillin and potassium clavulanate dosage form |
| WO2002041876A1 (en) * | 2000-11-22 | 2002-05-30 | Lupin Limited | Pharmaceutical composition for controlled release of an active ingredient |
| US20030070584A1 (en) * | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing cellulose ethers |
| AU4061702A (en) * | 2001-05-15 | 2003-04-03 | Mcneil-Ppc, Inc. | Dip coating compositions containing starch or dextrin |
| US20030072731A1 (en) * | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing starch or dextrin |
| US8329216B2 (en) * | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
| AU2002316582B2 (en) * | 2001-07-06 | 2007-03-15 | Endo Pharmaceuticals, Inc. | Oral administration of 6-hydroxy-oxymorphone for use as an analgesic |
| US6705028B2 (en) * | 2001-09-12 | 2004-03-16 | Honda Giken Kogyo Kabushiki Kaisha | Self-propelled snowplow vehicle |
| WO2003026743A2 (en) * | 2001-09-26 | 2003-04-03 | Penwest Pharmaceuticals Company | Opioid formulations having reduced potential for abuse |
| US8309118B2 (en) * | 2001-09-28 | 2012-11-13 | Mcneil-Ppc, Inc. | Film forming compositions containing sucralose |
| DE60117712T2 (de) * | 2001-11-19 | 2006-11-16 | Lupin Ltd., Mumbai | Pharmazeutische zusammensetzung für die kontrollierte freisetzung eines beta-lactam-antibiotikums |
| AU2003215671A1 (en) * | 2002-03-22 | 2003-10-08 | Cilag Ag | Sustained release formulation of tramadol |
| US7429619B2 (en) * | 2002-08-02 | 2008-09-30 | Mcneil Consumer Healthcare | Polyacrylic film forming compositions |
| RU2005122008A (ru) * | 2002-12-13 | 2006-02-10 | Цилаг Аг (Ch) | Препараты с контролируемым высвобождением, содержащие трамадол и топирамат |
| WO2004058152A2 (en) * | 2002-12-16 | 2004-07-15 | Ranbaxy Pharmaceuticals Inc. | An extended release pharmaceutical composition of phenytoin sodium |
| EP1603548A4 (en) * | 2003-02-05 | 2007-10-10 | Myriad Genetics Inc | METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES |
| US8802139B2 (en) * | 2003-06-26 | 2014-08-12 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
| JP2007528857A (ja) * | 2003-07-11 | 2007-10-18 | ミリアド ジェネティクス， インコーポレイテッド | アルツハイマー病の処置のための薬学的方法、投与レジメンおよび投薬形態 |
| ATE390122T1 (de) * | 2003-09-01 | 2008-04-15 | Jpm The Jordanian Pharmaceutic | Universelle zusammensetzung zur kontrollierten wirkstofffreigabe enthaltend xanthangummi und natriumalginat |
| US20050202079A1 (en) * | 2004-03-15 | 2005-09-15 | Mylan Pharmaceuticals Inc. | Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation |
| ES2244324B1 (es) * | 2004-03-25 | 2006-11-16 | Ferrer Internacional, S.A. | Composiciones diureticas de liberacion prolongada. |
| WO2006001877A2 (en) * | 2004-04-13 | 2006-01-05 | Myriad Genetics, Inc. | Combination treatment for neurodegenerative disorders comprising r-flurbiprofen |
| WO2005108683A1 (en) * | 2004-04-29 | 2005-11-17 | Keystone Retaining Wall Systems, Inc. | Veneers for walls, retaining walls and the like |
| US8394409B2 (en) * | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
| WO2006020853A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
| WO2006020850A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
| WO2006020852A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
| US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
| CN104958270A (zh) | 2004-08-25 | 2015-10-07 | 伊森舍丽斯有限公司 | 钾atp通道开放剂的药物制剂及其应用 |
| US20070077297A1 (en) * | 2004-09-30 | 2007-04-05 | Scolr Pharma, Inc. | Modified release ibuprofen dosage form |
| CA2584469A1 (en) * | 2004-10-26 | 2006-05-04 | Mcneil-Ppc, Inc. | Burst-release polymer composition and dosage forms comprising the same |
| WO2006123357A2 (en) * | 2005-02-22 | 2006-11-23 | Sun Pharmaceutical Industries Limited | Oral controlled release composition containing levetiracetam |
| US9757384B2 (en) | 2005-04-06 | 2017-09-12 | Essentialis, Inc. | Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome |
| EP1909777A2 (en) * | 2005-07-22 | 2008-04-16 | Myriad Genetics, Inc. | High drug load formulations and dosage forms |
| US20070036859A1 (en) * | 2005-08-11 | 2007-02-15 | Perry Ronald L | Sustained release antihistamine and decongestant composition |
| NZ569813A (en) * | 2005-12-16 | 2011-07-29 | Hanmi Holdings Co Ltd | Solid dispersion comprising an active ingredient having a low melting point and an absorbent, and a tablet for oral administration comprising same |
| US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
| AU2006335153B2 (en) | 2006-01-05 | 2012-03-15 | Essentialis, Inc. | Salts of potassium ATP channel openers and uses thereof |
| US8309104B2 (en) * | 2006-03-02 | 2012-11-13 | Watson Pharmaceuticals, Inc. | Oral controlled release formulation for sedative and hypnotic agents |
| US20070212414A1 (en) * | 2006-03-08 | 2007-09-13 | Penwest Pharmaceuticals Co. | Ethanol-resistant sustained release formulations |
| CN104825397A (zh) * | 2006-04-03 | 2015-08-12 | 伊萨·奥迪迪 | 含有机溶胶涂层的受控释放递送物件 |
| US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
| WO2008006099A2 (en) * | 2006-07-07 | 2008-01-10 | Myriad Genetics, Inc. | Treatment of psychiatric disorders |
| US7749537B2 (en) * | 2006-12-04 | 2010-07-06 | Scolr Pharma, Inc. | Method of forming a tablet |
| US20080318994A1 (en) * | 2007-06-21 | 2008-12-25 | Endo Pharmaceuticals, Inc. | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment |
| US20090124650A1 (en) * | 2007-06-21 | 2009-05-14 | Endo Pharmaceuticals, Inc. | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol |
| US20080318993A1 (en) * | 2007-06-21 | 2008-12-25 | Endo Pharmaceuticals, Inc. | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Hepatic Impairment |
| WO2009006483A1 (en) * | 2007-07-02 | 2009-01-08 | Essentialis, Inc. | Salts of potassium atp channel openers and uses thereof |
| DE102007032662A1 (de) * | 2007-07-13 | 2009-01-22 | Beiersdorf Ag | Kosmetische oder dermatologische Zubereitungen enthaltend ein oder mehrere Apiogalacturonane oder einen oder mehrere Apiogalacturonane enthaltenden Extrakt aus Zostera marina und einen zusätzlichen Gehalt an einem oder mehreren Hydrokolloiden |
| ES2600894T3 (es) * | 2010-02-22 | 2017-02-13 | Daiichi Sankyo Company, Limited | Preparación sólida de liberación sostenida para uso oral |
| US20140363508A1 (en) * | 2011-12-23 | 2014-12-11 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Pharmaceutical formulations of flurbiprofen and glucosamin |
| EP2797583B1 (en) | 2011-12-27 | 2015-09-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Combined pharmaceutical formulation containing diacerein |
| EP2819675A4 (en) | 2012-02-27 | 2015-07-22 | Essentialis Inc | SALTS OF KALIUM ATP CHANNEL OPENERS AND USES THEREOF |
| WO2014007777A1 (en) | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Combined capsule formulations of nsaids |
| WO2014007778A1 (en) | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | COMBINED IMMEDIATE RELEASE FORMULATIONS OF NSAIDs |
| PL3217963T3 (pl) | 2014-11-14 | 2020-10-19 | Essentialis, Inc. | Sposoby leczenia osobników z zespołem pradera-williego lub smith-magenis |
| CN108904451A (zh) * | 2018-07-27 | 2018-11-30 | 广州柏赛罗药业有限公司 | 缓释制剂 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901111A (fr) * | 1943-08-31 | 1945-07-18 | Perfectionnement aux dispositifs de réglage de terrage des charruesbascules | |
| US3065143A (en) | 1960-04-19 | 1962-11-20 | Richardson Merrell Inc | Sustained release tablet |
| FR2138492A1 (en) * | 1971-05-27 | 1973-01-05 | Cerm Cent Europ Rech Mauvernay | Basic aluminium salts of gum xanthane - pharmaceutical gelling agents |
| DE2130545A1 (de) | 1971-06-19 | 1972-12-21 | Merck Patent Gmbh | Pharmazeutischer Formkoerper |
| US4163777A (en) * | 1977-04-29 | 1979-08-07 | Lewis/Howe Company | Controlled antacid delivery form and method of treatment therewith |
| JPS5470420A (en) * | 1977-11-10 | 1979-06-06 | Sanei Kagaku Kogyo Kk | Binder for medical tablet |
| US4309405A (en) * | 1979-08-09 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
| US4248858A (en) * | 1979-08-09 | 1981-02-03 | American Home Products Corporation | Sustained release pharmaceutical compositions |
| NZ195933A (en) * | 1980-01-11 | 1982-11-23 | Boots Co Ltd | Sustained-release pharmaceutical compositions in tablet form |
| CA1207231A (en) * | 1982-08-24 | 1986-07-08 | Hans W. Zulliger | Medicated suppository |
| US4717713A (en) * | 1983-10-31 | 1988-01-05 | Research Corporation | Controlled release liquid pharmaceutical |
| JPS60219238A (ja) * | 1984-04-14 | 1985-11-01 | Hayashibara Biochem Lab Inc | 徐崩性プルラン含有成形物とその製法 |
| US4610870A (en) * | 1984-10-05 | 1986-09-09 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| GB8426152D0 (en) * | 1984-10-16 | 1984-11-21 | Reckitt & Colmann Prod Ltd | Medicinal compositions |
| DE3440288C2 (de) * | 1984-11-05 | 1987-03-12 | Gergely, Gerhard, Dr.-Ing., Wien | Pharmazeutische Zubereitung mit einem Gehalt an Ibuprofen sowie Verfahren zu ihrer Herstellung |
| BE901111A (fr) * | 1984-11-22 | 1985-03-15 | Benfar Representee Par Vanderl | Composition pharmaceutiques a liberation prolongee, leur procede de preparation et leur utilisation. |
| EP0182772A3 (fr) * | 1984-11-22 | 1987-04-01 | Benfar | Compositions pharmaceutiques à libération prolongée, leur procédé de préparation et leur utilisation |
| JPS61130239A (ja) * | 1984-11-30 | 1986-06-18 | Dai Ichi Seiyaku Co Ltd | 複合体 |
| US4747881A (en) * | 1985-02-05 | 1988-05-31 | Warner-Lambert Company | Ingestible aggregate and delivery system prepared therefrom |
| GB8507779D0 (en) * | 1985-03-26 | 1985-05-01 | Fujisawa Pharmaceutical Co | Drug carrier |
| US4666705A (en) * | 1985-06-03 | 1987-05-19 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| IT1191674B (it) * | 1986-03-07 | 1988-03-23 | Eurand Spa | Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale |
| US4994276A (en) * | 1988-09-19 | 1991-02-19 | Edward Mendell Co., Inc. | Directly compressible sustained release excipient |
-
1986
- 1986-01-18 GB GB868601204A patent/GB8601204D0/en active Pending
- 1986-12-31 IE IE342086A patent/IE59333B1/en not_active IP Right Cessation
-
1987
- 1987-01-06 AT AT87300035T patent/ATE77548T1/de not_active IP Right Cessation
- 1987-01-06 DE DE8787300035T patent/DE3779933T2/de not_active Expired - Lifetime
- 1987-01-06 EP EP87300035A patent/EP0234670B1/en not_active Expired - Lifetime
- 1987-01-06 ES ES87300035T patent/ES2042541T4/es not_active Expired - Lifetime
- 1987-01-07 IN IN9/MAS/87A patent/IN164250B/en unknown
- 1987-01-12 ZA ZA87173A patent/ZA87173B/xx unknown
- 1987-01-13 NZ NZ218907A patent/NZ218907A/xx unknown
- 1987-01-13 DK DK198700148A patent/DK175215B1/da not_active IP Right Cessation
- 1987-01-14 MY MYPI87000032A patent/MY100721A/en unknown
- 1987-01-15 FI FI870155A patent/FI93608C/fi not_active IP Right Cessation
- 1987-01-15 MX MX494987A patent/MX4949A/es unknown
- 1987-01-16 PH PH34733A patent/PH26408A/en unknown
- 1987-01-16 CA CA000527498A patent/CA1313133C/en not_active Expired - Fee Related
- 1987-01-16 NO NO870181A patent/NO173317C/no not_active IP Right Cessation
- 1987-01-16 JP JP62006312A patent/JPH0669965B2/ja not_active Expired - Lifetime
- 1987-01-16 IL IL81281A patent/IL81281A/xx not_active IP Right Cessation
- 1987-01-16 AU AU67625/87A patent/AU608208B2/en not_active Ceased
- 1987-01-16 PT PT84133A patent/PT84133B/pt unknown
- 1987-01-17 KR KR1019870000334A patent/KR940011242B1/ko not_active Expired - Fee Related
-
1991
- 1991-04-19 US US07/687,090 patent/US5415871A/en not_active Expired - Lifetime
- 1991-06-28 AU AU79462/91A patent/AU628754B2/en not_active Ceased
-
1992
- 1992-09-24 GR GR920402118T patent/GR3005796T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK175215B1 (da) | Fast farmaceutisk præparat med langvarig afgivelse af det aktive stof samt fremgangsmåde til fremstilling deraf | |
| JP4919801B2 (ja) | 高い薬剤配合量を提供する薬剤コーティング及びそれを提供する方法 | |
| JPH08512062A (ja) | 一日一回投与用のメトプロロール剤形 | |
| JPH08511807A (ja) | メトプロロールの２４時間放出用の徐放性調剤 | |
| WO2003103634A1 (en) | Sustained release oral dosage forms of gabapentin | |
| JPS62501845A (ja) | 制御放出塩化カリウム | |
| HUE031251T2 (en) | Controlled release oral dosage form containing oxycodone | |
| US8460702B2 (en) | Pharmaceutical compositions | |
| AU2012300815A1 (en) | Oral formulations containing hyaluronic acid for sustained drug release | |
| CN108514560B (zh) | 一种来那度胺胃滞留缓释片及其制备方法 | |
| JP3552285B2 (ja) | 経口コレステロール低下剤 | |
| CN110787143A (zh) | 一种盐酸二甲双胍片剂及其应用 | |
| CN110693845A (zh) | 盐酸二甲双胍缓释片的制备工艺 | |
| CN101138556B (zh) | 特比萘芬或其盐成膜凝胶组合物及其应用 | |
| EP1100471B1 (en) | Compressed compositions comprising clarified xanthan gum | |
| CA2343270C (en) | Methazolamide compositions and method of use | |
| CN115105478B (zh) | 一种拉考沙胺药物组合物、其制备方法及应用 | |
| CN100446814C (zh) | 复方硝酸益康唑成膜凝胶组合物及其制药用途 | |
| JP2021120397A (ja) | 低１日用量で投与するためのフマル酸ジメチルを含む医薬組成物 | |
| CN101138541A (zh) | 氨来占诺局部成膜凝胶组合物及其应用 | |
| CA3058933A1 (en) | Tesofensine for reduction of body weight in prader-willi patients | |
| CA3029052A1 (en) | Tesofensine for reduction of body weight in prader-willi patients | |
| Vishwanathrao | Formulation and Evaluation of Sustained Release Matrix Tablets of Salbutamol Sulphate Using Various Polymers | |
| JPH11246392A (ja) | 経口用固形製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PBP | Patent lapsed |
Country of ref document: DK |